All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
During the 16th International Conference on Malignant Lymphoma (16-ICML), the Lymphoma Hub spoke with Björn Chapuy, Universitätsmedizin Göttingen, Göttingen, DE, and Leticia Quintanilla-Martinez de Fend, University Hospital Tübingen, Tübingen, DE. We asked, What is the role of genetic classification in the diagnosis of diffuse large B-cell lymphoma (DLBCL)?
What is the role of genetic classification in the diagnosis of DLBCL?
Chapuy and de Fend begin by discussing the role of genetic classification and heterogeneity in DLBCL and explore the current obstacle of how to utilize this in routine diagnostics. They go on to highlight the need for clinical trials, and Chapuy outlines a novel clinical trial presented at ICML. Finally, they recap the journey from refining molecular understanding to clinical decision-making.
Tisagenlecleucel in secondary CNS lymphoma
A retrospective analysis of a small number of patients with high-grade B-cell NHL and secondary CNS involvement, who were treated with commercial tisagenlecleucel (tisa).
FDA approves rituximab-pvvr (Ruxience®), a rituximab biosimilar, for the treatment of patients with CD20-positive NHL and CLL
On 23 July 2019, the FDA approved rituximab-pvvr (Ruxience®), a monoclonal antibody biosimilar to rituximab, for multiple...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox